November 28, 2016 - By Adrian Mccoy
Advanced Oncotherapy PLC (LON:AVO) stock had its “Speculative Buy” Rating reiterated by research professionals at Beaufort Securities in a report shared with investors on Monday morning.
About 425,360 shares traded hands or 313.70% up from the average. Advanced Oncotherapy PLC (LON:AVO) has declined 57.24% since April 28, 2016 and is downtrending. It has underperformed by 63.25% the S&P500.
Advanced Oncotherapy Plc is focused on providing radiotherapy systems for cancer treatment through the use of a proton therapy technology. The company has a market cap of 45.06 million GBP. The Firm is engaged in development and then building of the Linac Image Guided Hadron Technology proton beam cancer therapy device and management of healthcare related property. It currently has negative earnings. The Company’s divisions include Development of Proton Therapy-UK; Development of Proton Therapy-Switzerland; Development of Proton Therapy-USA, and Healthcare-related properties-UK.
The Aveon Group L.P. (Aveon) is an investment management firm focused on acquiring controlling interests in the general partners or managing members of a diversified group of hedge funds, which it refers to as its manager affiliates. The Firm seeks to acquire its interest in each of its six initial manager affiliates, which has investment track records ranging from 5 to 19 years. Each of Aveonâ€™s manager affiliates has assets under management (assets under management or AUM) of less than $1 billion and generally focuses on a single investment strategy. The Aveon Group L.P. has formed wholly owned subsidiaries to serve as the general partners of the three Aveon Holdings partnerships: Aveon Holdings I GP Inc., Aveon Holdings II GP L.P. and Aveon Holdings III GP L.P.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy